Reviewer's report

**Title:** Optimising plasma levels of clozapine during metabolic interactions: a review and case report with adjunct rifampicin treatment.

**Version:** 1  
**Date:** 30 June 2014

**Reviewer:** Nagesh Pai

**Reviewer's report:**

This case report presents a previously reported adverse interactions involving clozapine therapy. However authors shed new light on the possible educational value as they highlight the guidelines for clinicians to manage these important drug interactions.

I do not have any reasons to believe that research has been falsified or manipulated.

Graphic illustration of clozapine levels to medication initiation and stopping helps the reader understand the concepts behind the case report in a lucid manner. (Fig 2) Abstract conclusion -'guidance to clinicians in managing metabolic interactions between clozapine and rifampicin' could have been read as drug interactions Typological error-reference 4 (325)-It should be read as patients Discretionary Revisions- Under principles be used to ensure effective and safe treatment of a psychotic illness with Clozapine when co-administering a course of TB therapy- 'It may be necessary to exceed the licensed maximum dose of clozapine to attain a therapeutic plasma level." Rationale for such guideline would beneficial.

**Level of interest:** An article whose findings are important to those with closely related research interests

**Quality of written English:** Acceptable

**Statistical review:** No, the manuscript does not need to be seen by a statistician.

**Declaration of competing interests:**

I declare that I have no competing interests